Skip to main content
Equibles
GRPS logo

GRPS · Trans American Aquaculture, Inc

Track GRPS — free

Use GRPS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GRPS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Aug 11
Rebalance outlook locked
Going-concern doubt — flagged Jan 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, as relative to capital raising activities, create doubt as to our ability to continue as a going concern.”
View the 10-Q filed Jan 14, 2026
Market Cap
$180,592
Shares
1.81B
Volume · Aug 11 1.65M Avg daily vol (3M) 1.58M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.00 Avg vol 30d1.5M Short int115 · 0.0% of shares · 1.0d Short vol100% DataJan 2020–Aug 2026 Filing10-Q · Jan 14

Latest documents

2026
Jan 14
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3 AI summary on its way
Revenue $0 Net loss $171.64K Diluted EPS -$0.00
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$16,500
Trailing 12 months
Net income (TTM)
−$2.15M
Trailing 12 months
Revenue growth YoY
+226.5%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$47,771
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-50.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
· $0 −$768,218 '23 Q3 · $310,126 −$238,021 '24 Q1 · $5,019 −$330,311 '24 Q2 · $0 −$575,325 '24 Q3 · $16,500 −$1.67M '24 Q4* ▼100% $0 −$113,707 '25 Q1 ▼100% $0 −$204,038 '25 Q2 LATEST · $0 −$171,642 '25 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −50%
below
Price vs 50-day avg −67%
below
RSI (14) 27
oversold
MACD trend Positive
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −67%
trailing
6-month return −80%
trailing
YTD return −67%
this year
Relative strength −92%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 13
low risk · 0–100
Fundamentals
Fair
Revenue growth +227%
Y/Y
Gross margin 3%
expanding
EPS growth −22%
Y/Y
Balance sheet $54.5K
net debt
Quant / Vol
risk profile
High
Volatility 485%
annualized · 1-yr
Max drawdown −80%
past year
ATR 0.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−50% Bearish
Price vs 50-day avg
−67% Bearish
RSI (14)
27 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $0
vs 200-day avg -50% vs 50-day avg -67%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GRPS
Trans American Aquaculture, Inc
this stock
$180,592 -66.7% +226.5% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $67.48B +35.5% — — 0.1%
GALDY
Galderma Group AG
 $54.01B +11.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $50.93B +39.9% +4.3% 99.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
115
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
217.5K
Value
$2.2K
As of
Nov 15, 2022
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$331.6K
Net income (FY)
$-2.8M
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 17, 2026
This year
5
View
Exempt Offerings
Offering
$104.0K
Filed
Apr 11, 2025
View

Performance

5D 20D 120D MTD YTD
GRPS -50.0% -66.7% -80.0% -50.0% -66.7%
SPY -0.1% +2.5% +12.3% +3.2% +13.0%
vs SPY -49.9% -69.2% -92.3% -53.2% -79.7%
Key facts CIK 1990446